US 7,541,478 B2
	Coumarin derivative and use thereof
Shogo Marui, Osaka (Japan); Masaki Ogino, Osaka (Japan); Hiroyuki Tawada, Osaka (Japan); and Osamu Yabe, Osaka (Japan)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (Japan)
Appl. No. 10/591,561 PCT Filed Mar. 01, 2005, PCT No. PCT/JP2005/003838 § 371(c)(1), (2), (4) Date Aug. 31, 2006, PCT Pub. No. WO2005/082879, PCT Pub. Date Sep. 09, 2005.
Claims priority of application No. 2004-057920 (JP), filed on Mar. 02, 2004.
Prior Publication US 2007/0197636 A1, Aug. 23, 2007
Int. Cl. C07D 311/02 (2006.01)

U.S. Cl. 549—283  [549/285; 549/288]

3 Claims

1. A compound selected from the group consisting of monocalcium bis((2E)-3-[3-[7-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]acrylate) and (2E)-3-[3-[7-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]acrylate tris(hydroxymethyl)methylamine salt, or a hydrate thereof, with the hydration number in the range of monohydrate to tetrahydrate.